$SMTI
Sanara MedTech Inc. Stock $smti

$smti Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224018880 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$20.16M	$18.54M	$15.52M
YoY Change	27.97%	19.42%	98.71%
Cost Of Revenue	$2.009M	$1.890M	$2.126M
YoY Change	-8.18%	-11.08%	164.03%
Gross Profit	$18.15M	$16.65M	$13.40M
YoY Change	33.79%	24.26%	91.21%
Gross Profit Margin	90.04%	89.8%	86.31%
Selling, General & Admin	$18.96M	$16.19M	$12.97M
YoY Change	37.26%	24.85%	38.33%
% of Gross Profit	104.45%	97.27%	96.81%
Research & Development	$985.7K	$946.3K	$1.317M
YoY Change	-16.27%	-28.17%	543.73%
% of Gross Profit	5.43%	5.68%	9.83%
Depreciation & Amortization	$133.3K	$133.0K	$107.7K
YoY Change	22.87%	23.49%	-46.89%
% of Gross Profit	0.73%	0.8%	0.8%
Operating Expenses	$21.03M	$18.18M	$14.61M
YoY Change	36.31%	24.4%	49.37%
Operating Profit	-$2.885M	-$1.532M	-$1.216M
YoY Change	54.59%	25.93%	-56.2%
Interest Expense	$644.3K	$267.3K	$6.00
YoY Change		4455500.0%
% of Operating Profit
Other Income/Expense, Net	-$644.3K	-$267.3K	-$6.00
YoY Change		4455500.0%	-100.0%
Pretax Income	-$3.529M	-$1.799M	-$1.216M
YoY Change	89.11%	47.91%	-61.47%
Income Tax
% Of Pretax Income
Net Earnings	-$3.504M	-$1.764M	-$1.178M
YoY Change	91.71%	49.77%	-62.68%
Net Earnings / Revenue	-17.38%	-9.52%	-7.59%
Basic Earnings Per Share	-$0.41	-$0.21	-$0.14
Diluted Earnings Per Share	-$0.41	-$0.21	-$0.14
COMMON SHARES
Basic Shares Outstanding	8.625M shares	8.623M shares	8.377M shares
Diluted Shares Outstanding	8.469M shares	8.420M shares	8.174M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.150M	$2.828M	$7.286M
YoY Change	1.49%	-61.19%	-54.86%
Cash & Equivalents	$6.150M	$2.828M	$7.286M
Short-Term Investments
Other Short-Term Assets	$489.2K	$911.6K	$1.748M
YoY Change	0.72%	-47.86%	179.77%
Inventory	$3.565M	$4.229M	$3.432M
Prepaid Expenses
Receivables	$10.61M	$9.218M	$6.541M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.81M	$17.19M	$19.01M
YoY Change	14.49%	-9.58%	-15.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.116M	$1.191M	$1.336M
YoY Change	-10.0%	-10.86%	-30.93%
Goodwill	$3.602M	$3.602M	$3.602M
YoY Change	0.0%	0.0%
Intangibles	$42.98M	$43.95M	$30.84M
YoY Change	42.58%	42.53%
Long-Term Investments	$3.084M	$3.084M	$3.084M
YoY Change	0.0%	0.0%	-36.9%
Other Assets
YoY Change
Total Long-Term Assets	$52.57M	$53.73M	$40.96M
YoY Change	31.1%	31.17%	258.05%
TOTAL ASSETS
Total Short-Term Assets	$20.81M	$17.19M	$19.01M
Total Long-Term Assets	$52.57M	$53.73M	$40.96M
Total Assets	$73.38M	$70.91M	$59.97M
YoY Change	25.92%	18.25%	76.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$896.0K	$1.279M	$1.821M
YoY Change	-19.48%	-29.78%	85.62%
Accrued Expenses	$9.584M	$9.559M	$8.094M
YoY Change	18.79%	18.1%	90.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$928.6K
YoY Change
Total Short-Term Liabilities	$11.57M	$12.75M	$10.60M
YoY Change	17.05%	20.23%	102.67%
LONG-TERM LIABILITIES
Long-Term Debt	$14.37M	$8.768M	$0.00
YoY Change
Other Long-Term Liabilities	$2.654M	$2.778M	$6.028M
YoY Change	-53.06%	-53.91%	3122.63%
Total Long-Term Liabilities	$20.42M	$15.15M	$7.887M
YoY Change	174.67%	92.15%	4116.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.57M	$12.75M	$10.60M
Total Long-Term Liabilities	$20.42M	$15.15M	$7.887M
Total Liabilities	$31.98M	$27.90M	$18.49M
YoY Change	84.71%	50.91%	277.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$33.39M	-$29.90M	-$24.91M
YoY Change	24.86%	20.01%
Common Stock	$75.09M	$73.19M	$66.54M
YoY Change	10.61%	10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.71M	$43.29M	$41.62M
YoY Change
Total Liabilities & Shareholders Equity	$73.38M	$70.91M	$59.97M
YoY Change	25.92%	18.25%	76.72%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$3.504M	-$1.764M	-$1.178M
YoY Change	91.71%	49.77%	-62.68%
Depreciation, Depletion And Amortization	$133.3K	$133.0K	$107.7K
YoY Change	22.87%	23.49%	-46.89%
Cash From Operating Activities	-$1.412M	-$1.594M	-$1.741M
YoY Change	-17.9%	-8.44%	-17.57%
INVESTING ACTIVITIES
Capital Expenditures	$58.76K	$65.82K	$27.71K
YoY Change	354.1%	137.57%	-161.98%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$650.00
YoY Change		-100.0%	-100.26%
Cash From Investing Activities	-$58.76K	-$65.82K	-$27.06K
YoY Change	354.1%	143.27%	-90.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.793M	-$658.8K	$95.81K
YoY Change	846.1%	-787.6%	-193.08%
NET CHANGE
Cash From Operating Activities	-1.412M	-$1.594M	-$1.741M
Cash From Investing Activities	-58.76K	-$65.82K	-$27.06K
Cash From Financing Activities	4.793M	-$658.8K	$95.81K
Net Change In Cash	3.322M	-$2.319M	-$1.673M
YoY Change	-370.93%	38.65%	-33.36%
FREE CASH FLOW
Cash From Operating Activities	-$1.412M	-$1.594M	-$1.741M
Capital Expenditures	$58.76K	$65.82K	$27.71K
Free Cash Flow	-$1.471M	-$1.660M	-$1.769M
YoY Change	-15.13%	-6.15%	-14.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-39678
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	SANARA MEDTECH INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	TX
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-2219994
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Summit Ave
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 414
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Worth
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76102
CY2024Q1	dei	City Area Code CityAreaCode	(817)
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2024Q1	dei	Trading Symbol TradingSymbol	SMTI
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	SMTI	Royalty Receivable RoyaltyReceivable		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities		usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2024Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023Q1	SMTI	Cash Payment Of Deferred And Earnout Liabilities CashPaymentOfDeferredAndEarnoutLiabilities		usd
CY2024Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
CY2024Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive		usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2024Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2024Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2024Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2024Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	529-2300
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8625201	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2828234	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5147216	usd
CY2023Q4	SMTI	Royalty Receivable RoyaltyReceivable	49344	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	4229150	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4717533	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	911594	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	608411	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	17186779	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	19005869	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43953610	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44926061	usd
CY2024Q1	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1894687	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1995204	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1190805	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1257956	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	53725161	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	54865280	usd
CY2024Q1	us-gaap	Assets Assets	70911940	usd
CY2023Q4	us-gaap	Assets Assets	73871149	usd
CY2024Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	6893381	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7676770	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2288428	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2047678	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	979488	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1100000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	928571	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	580357	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	377273	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	361185	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	12746073	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13767877	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8767991	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9113123	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2777835	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2723001	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1626130	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1737445	usd
CY2024Q1	us-gaap	Other Long Term Debt OtherLongTermDebt	1982345	usd
CY2023Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1941686	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15154301	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15515255	usd
CY2024Q1	us-gaap	Liabilities Liabilities	27900374	usd
CY2023Q4	us-gaap	Liabilities Liabilities	29283132	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8622739	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8622739	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8535239	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8535239	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	8623	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8535	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	73180208	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72860556	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29898146	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28036814	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	43290685	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	44832277	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	-279119	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-244260	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43011566	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70911940	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73871149	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18536638	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15521917	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1890046	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	2125659	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	16646592	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	13396258	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16192259	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12969069	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	946298	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1317324	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1105420	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	778875	usd
CY2024Q1	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	65678	usd
CY2023Q1	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	452687	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	18178299	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	14612581	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1531707	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1216323	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	267336	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	6	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-267336	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1799043	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1216329	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34859	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-38429	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1764184	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1177900	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8419528	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8419528	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8173784	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8173784	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	597305	usd
CY2023Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-655942	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1033761	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1216329	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41478770	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	803386	usd
CY2024Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-580794	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1799043	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43011566	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43011566	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1799043	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1216329	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1105420	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	778875	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	65000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	36000	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	95235	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	30511	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	803386	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	597305	usd
CY2024Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	100517	usd
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	76545	usd
CY2024Q1	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities	58834	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3083	usd
CY2024Q1	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	65678	usd
CY2023Q1	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	452687	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	735490	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-352102	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	14602	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-74602	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-393148	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-86785	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	303182	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	361719	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-732266	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	405360	usd
CY2024Q1	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	9311	usd
CY2023Q1	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	-10747	usd
CY2024Q1	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	300574	usd
CY2023Q1	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	-112774	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-783390	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1949325	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-95227	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-75817	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1594370	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1741313	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	65818	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27705	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	650	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65818	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27055	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	751752	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-580794	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-655942	usd
CY2024Q1	SMTI	Cash Payment Of Deferred And Earnout Liabilities CashPaymentOfDeferredAndEarnoutLiabilities	78000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-658794	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95810	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2318982	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1672558	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5147216	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8958995	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2828234	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7286437	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	205591	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	6	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	282010	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1369164	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_804_eus-gaap--NatureOfOperations_zmH7nG5SH8Ol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82E_zudMeq7BmLB4">NATURE OF BUSINESS AND BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara MedTech Inc. (together with its wholly owned and majority owned subsidiaries on a consolidated basis, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Each of the Company’s products, services and technologies are designed to achieve the Company’s goal of providing better clinical outcomes at a lower overall cost for patients regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zO6KNDgddHH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2519898	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2454080	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1329093	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1196124	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1190805	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1257956	usd
CY2024Q1	us-gaap	Depreciation Depreciation	132969	usd
CY2023Q1	us-gaap	Depreciation Depreciation	107674	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18536638	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15521917	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	65000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	36000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	593030	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	528030	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3670	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3820	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	95235	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	30511	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	398478	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	446917	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3823001	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-65678	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3757323	usd
CY2023Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10000000.0	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	9750000	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Equity Shares AssetAcquisitionConsiderationTransferredEquityShares	73809	shares
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Stock Closing Consideration AssetAcquisitionConsiderationTransferredFairValueOfStockClosingConsideration	3089645	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Installment Payments AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments	2040808	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Cash Paid For Inventory AssetAcquisitionConsiderationTransferredCashPaidForInventory	30007	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Petito Services Defined Payments AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments	825834	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	893000	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	162743	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	16792037	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2024Q1	us-gaap	Goodwill Goodwill	3601781	usd
CY2024Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y6M
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	972451	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	671201	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2917353	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3889804	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3872548	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3758696	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3725454	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3725454	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	22064301	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	43953610	usd
CY2024Q1	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2023Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1894687	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2003403	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	138798	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	88419	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	133509	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	87691	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	371508	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	532053	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	379529	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	297947	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	295689	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	300158	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	604049	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2780933	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	777530	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2003403	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	377273	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1626130	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0765	pure
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2024Q1	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	8221	usd
CY2023Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	5138	usd
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	53438	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	56520	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	9696562	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	9693480	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	928571	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	580357	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8767991	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9113123	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	580357	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1625000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1950000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1950000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3644643	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2024Q1	us-gaap	Accumulated Amortization Of Noncurrent Deferred Finance Costs AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts	53438	usd
CY2023Q4	us-gaap	Accumulated Amortization Of Noncurrent Deferred Finance Costs AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts	56520	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3083	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	us-gaap	Cash Cash	693000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	SMTI	Earnout Payment EarnoutPayment	693000	usd
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	100662	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	7830959	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5859819	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	144211	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	34.07
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	105934	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	37.36
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	51656	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	32.03
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	5272	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	32.66
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	193217	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	36.46
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	93892	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.22
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3059	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.02
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	90833	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.16
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2438222.4	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	90833	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.16
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y7M6D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2438222.4	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2023Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2024Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2024Q1	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2024Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	16725	shares
CY2024Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	10.80
CY2024Q1	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2024Q1	us-gaap	Debt Current DebtCurrent	3000000.0	usd
CY2024Q1	SMTI	Annual Minimum Revenue AnnualMinimumRevenue	60000000.0	usd
CY2024Q1	SMTI	Annual Minimum Revenue Year One AnnualMinimumRevenueYearOne	75000000.0	usd
CY2024Q1	SMTI	Annual Minimum Revenue Year Two AnnualMinimumRevenueYearTwo	85000000.0	usd
CY2024Q1	SMTI	Annual Minimum Revenue Year Three AnnualMinimumRevenueYearThree	95000000.0	usd
CY2024Q1	SMTI	Annual Minimum Revenue Year Four AnnualMinimumRevenueYearFour	105000000.0	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-018880-index-headers.html	Edgar Link	pending
0001493152-24-018880-index.html	Edgar Link	pending
0001493152-24-018880.txt	Edgar Link	pending
0001493152-24-018880-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smti-20240331.xsd	Edgar Link	pending
smti-20240331_cal.xml	Edgar Link	unprocessable
smti-20240331_def.xml	Edgar Link	unprocessable
smti-20240331_lab.xml	Edgar Link	unprocessable
smti-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMTI
Sanara MedTech Inc. Stock $smti

2024 Q2 Form 10-Q Financial Statement

#000149315224018880 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI Sanara MedTech Inc. Stock $smti

2024 Q2 Form 10-Q Financial Statement

#000149315224018880 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI
Sanara MedTech Inc. Stock $smti